NO20076663L - Immunoglobuliner - Google Patents

Immunoglobuliner

Info

Publication number
NO20076663L
NO20076663L NO20076663A NO20076663A NO20076663L NO 20076663 L NO20076663 L NO 20076663L NO 20076663 A NO20076663 A NO 20076663A NO 20076663 A NO20076663 A NO 20076663A NO 20076663 L NO20076663 L NO 20076663L
Authority
NO
Norway
Prior art keywords
immunoglobulins
antibodies
disorders
prevention
treatment
Prior art date
Application number
NO20076663A
Other languages
English (en)
Inventor
Jonathan Henry Ellis
Alan Peter Lewis
Paul A Hamblin
Farhana Hussain
Ruth Mcadam
Paul Alexander Wilson
Rabinder Kumar Prinjha
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0513766A external-priority patent/GB0513766D0/en
Priority claimed from GB0525448A external-priority patent/GB0525448D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of NO20076663L publication Critical patent/NO20076663L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SAMMENDRAG Foreliggende oppfinnelse angår antistoffer mot NOGO, farmasøytiske formuleringer inneholdende dem og anvendelse av slike antistoffer ved behandling og/eller forebygging av nevrologiske sykdommer/lidelser.
NO20076663A 2005-07-05 2007-12-28 Immunoglobuliner NO20076663L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0513766A GB0513766D0 (en) 2005-07-05 2005-07-05 Immunoglobulins
GB0525448A GB0525448D0 (en) 2005-12-14 2005-12-14 Immunoglobulins
PCT/EP2006/006535 WO2007003421A2 (en) 2005-07-05 2006-07-03 Humanised antibodies specific for nogo-a and pharmaceutical uses thereof

Publications (1)

Publication Number Publication Date
NO20076663L true NO20076663L (no) 2008-02-27

Family

ID=37604821

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20076663A NO20076663L (no) 2005-07-05 2007-12-28 Immunoglobuliner

Country Status (21)

Country Link
EP (1) EP1899377B1 (no)
JP (1) JP2009500363A (no)
KR (1) KR20080030960A (no)
AU (1) AU2006265276B2 (no)
BR (1) BRPI0612734A2 (no)
CA (1) CA2614076A1 (no)
CR (1) CR9623A (no)
CY (1) CY1113310T1 (no)
DK (1) DK1899377T3 (no)
EA (1) EA014291B1 (no)
ES (1) ES2391902T3 (no)
HR (1) HRP20120851T1 (no)
IL (1) IL188282A (no)
MA (1) MA29625B1 (no)
NO (1) NO20076663L (no)
NZ (1) NZ564567A (no)
PL (1) PL1899377T3 (no)
PT (1) PT1899377E (no)
SG (1) SG162829A1 (no)
SI (1) SI1899377T1 (no)
WO (1) WO2007003421A2 (no)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2417065T3 (es) 2005-04-26 2013-08-05 Trion Pharma Gmbh Combinación de anticuerpos con glucocorticoides para el tratamiento del cáncer
DK2158315T3 (en) 2007-06-25 2016-06-06 Esbatech Alcon Biomed Res Unit Methods of modifying antibodies and modified antibodies with improved functional properties
AU2008317724B2 (en) * 2007-11-02 2011-06-02 Novartis Ag Improved Nogo-A binding molecules and pharmaceutical use thereof
WO2010004031A2 (en) * 2008-07-11 2010-01-14 Glaxo Group Limited Novel treatment
GB201709970D0 (en) 2017-06-22 2017-08-09 Kymab Ltd Bispecific antigen-binding molecules
US20220064327A1 (en) 2018-12-21 2022-03-03 Kymab Limited Fixaxfx bispecific antibody with common light chain
GB2590642B (en) * 2019-12-20 2024-02-14 Kymab Ltd Improved lambda antibodies

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0228832D0 (en) * 2002-12-10 2003-01-15 Novartis Ag Organic compound
GB0321997D0 (en) * 2003-09-19 2003-10-22 Novartis Ag Organic compound
US7988964B2 (en) * 2003-12-22 2011-08-02 Glaxo Group Limited NOGO-a neutralising immunoglobulin for treatment of neurological diseases

Also Published As

Publication number Publication date
NZ564567A (en) 2010-09-30
ES2391902T3 (es) 2012-11-30
EA014291B1 (ru) 2010-10-29
WO2007003421A2 (en) 2007-01-11
IL188282A (en) 2011-04-28
IL188282A0 (en) 2008-04-13
PT1899377E (pt) 2012-11-20
CY1113310T1 (el) 2016-04-13
BRPI0612734A2 (pt) 2010-11-30
WO2007003421A3 (en) 2007-04-12
EA200702634A1 (ru) 2008-06-30
PL1899377T3 (pl) 2013-01-31
AU2006265276B2 (en) 2011-10-13
EP1899377A2 (en) 2008-03-19
SI1899377T1 (sl) 2012-12-31
CR9623A (es) 2008-04-10
KR20080030960A (ko) 2008-04-07
HK1115598A1 (en) 2008-12-05
MA29625B1 (fr) 2008-07-01
CA2614076A1 (en) 2007-01-11
JP2009500363A (ja) 2009-01-08
HRP20120851T1 (hr) 2012-11-30
EP1899377B1 (en) 2012-08-22
SG162829A1 (en) 2010-07-29
DK1899377T3 (da) 2012-11-12
AU2006265276A1 (en) 2007-01-11

Similar Documents

Publication Publication Date Title
NO20062767L (no) Immunoglobuliner
NO20082699L (no) Immunoglobuliner
WO2008079246A3 (en) Cd44 antibodies
NO20070049L (no) Pyrrolotriazinderivater anvendelig for behandling av hyperproliferative forstyrrelser og sykdommer assosiert med angiogenese
DE602005027707D1 (de) Isoindolin-verbindungen und deren verwendungen
WO2007064883A3 (en) Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
EA201000424A1 (ru) Антитела к il-23
EA200901263A1 (ru) Конденсированный аминопиридин в качестве ингибиторов hsp90
NO20055894L (no) Fremgangsmater og blandinger for behandling av amyloidrelatertere sykdommer
NO20045323L (no) Antistoffer
WO2006058868A8 (de) Substituierte pteridine zur behandlung von entzündlichen erkrankungen
WO2006096489A3 (en) Anti-m-csf antibody compositions having reduced levels of endotoxin
WO2005116088A3 (en) Methods and compositions for treating diseases and disorders associated with siglec-8 expressing cells
WO2009071689A3 (de) 5-halogen-substituierte oxindol-derivate und ihre verwendung zur behandlung von vasopressin-abhängigen erkrankungen
WO2006058867A3 (de) Substituierte pteridine zur behandlung von entzündlichen erkrankungen
CY1113310T1 (el) Εξανθρωπισμενα αντισωματα ειδικα για nogo-a και φαρμακευτικες χρησεις αυτων
WO2007050793A3 (en) Methods and compositions for the treatment of marfan syndrome and associated disorders
WO2006058869A8 (de) Substituierte pteridine zur behandlung von entzündlichen erkrankungen
UA90698C2 (en) Triazole substituted aminobenzophenone compounds
WO2007059341A3 (en) Pyrazolothiazole protein kinase modulators
WO2005092062A3 (en) Compounds for neurodegenerative disorders
WO2007017146A3 (en) Use of collismycin and derivatives thereof as oxidative stress inhibitors
WO2006110447A3 (en) Pyrimidine derivatives and their use in the treatment of cancer
WO2005107464A3 (en) Compounds and compositions as cathepsin s inhibitors
UA87851C2 (ru) Производные пирролотриазина, применимые для лечения гиперпролиферативных нарушений и заболеваний, связанных с ангиогенезом

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: GLAXO GROUP LTD, GB

FC2A Withdrawal, rejection or dismissal of laid open patent application